Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation

MLA

Marie Bienvenu-Perrard, et al. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. Apr. 2017. EBSCOhost, https://doi.org/10.1089/thy.2016.0334⟩.

APA

Marie Bienvenu-Perrard, Anne-Cécile Paepegaey, Najiba Lahlou, Lionel Groussin, Estelle Louiset, Léopoldine Bricaire, Béatrix Cochand-Priollet, Marco Alifano, Nelly Burnichon, & Pierre-Olivier Sarfati. (2017). Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. https://doi.org/10.1089/thy.2016.0334⟩

Chicago

Marie Bienvenu-Perrard, Anne-Cécile Paepegaey, Najiba Lahlou, Lionel Groussin, Estelle Louiset, Léopoldine Bricaire, Béatrix Cochand-Priollet, Marco Alifano, Nelly Burnichon, and Pierre-Olivier Sarfati. 2017. “Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation,” April. doi:10.1089/thy.2016.0334⟩.